Cash Trust Series Government Cas Stock Quote CTGXX - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Previous Close

Open

Last Trade

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today...

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal...

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Reports Results of 2024 Annual General Meeting

BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer...

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported...

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced...

Form D/A - Notice of Exempt Offering of Securities: [Amend]

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PMECPrimech Holdings Ltd	$ 0.9934 (88.79%)	75.61M
NCNCnoco noco Inc	$ 0.2726 (78.17%)	244.76M
NUZENuZee Inc	$ 6.12 (65.41%)	32.2M
POWLPowell Industries Inc	$ 176.60 (32.53%)	1.01M
RENBRenovaro Inc	$ 0.872501 (30.24%)	8.04M
IMNNImunon Inc	$ 1.538 (-53.67%)	10.3M
FGENFibroGen Inc	$ 0.5163 (-49.87%)	9.95M
PEPGPepGen Inc	$ 9.45 (-44.35%)	949.79k
DHDefinitive Healthcare Corporation	$ 3.46 (-39.72%)	3.18M
TCBPTC BioPharm Holdings PLC	$ 0.60 (-35.06%)	394.5k
NCNCnoco noco Inc	$ 0.2726 (78.17%)	244.76M
NVDANVIDIA Corporation	$ 115.7304 (11.57%)	218.37M
PRSTPresto Technologies Inc	$ 0.038 (8.57%)	139.25M
SQQQProShares UltraPro Short QQQ	$ 8.655 (-8.22%)	111.01M
FFIEFaraday Future Intelligent Electric Inc	$ 0.3656 (15.70%)	104.58M